CLEVELAND, July 29, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Centre Oscar Lambret has selected a MRIdian MRI-Guided Radiation Therapy System. The center will be the first in Lille, France to offer advanced MRI-guided radiation therapy technology in the Hauts de France region.

Centre Oscar Lambret is exclusively dedicated to cancer treatment and research. The center has three main missions: care, research, and teaching. Its goal is to fast-track innovations in oncology for all patients in the Hauts-de-France region. Access to quality care is a priority for the Centre Oscar Lambret. The program currently has 151 clinical studies ongoing, and each year the radiation therapy department treats approximately 3,500 patients. Centre Oscar Lambret expects to begin treating patients early in 2024.

"We are pleased to welcome Centre Oscar Lambret to the MRIdian global community. With MRIdian, Centre Oscar Lambret will offer personalized treatment to a broader population of cancer patients." said Martin Fuss, M.D., Chief Medical Officer at ViewRay. "Through the use of MRI-guidance, on-table adaptive replanning capabilities, and the ability to control the radiation beam based on real-time MR-imaging during treatment, Centre Oscar Lambret will improve the accuracy with which they deliver radiation treatments. Patients will benefit from higher radiation doses delivered in fewer treatment sessions, even if they may have tumors that are today considered virtually untreatable."

The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.

Over 24,000 patients have been treated with MRIdian. Currently, 53 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.


About ViewRay
ViewRay, Inc. (NASDAQ: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.


SOURCE ViewRay, Inc.